ReviewDer Nervenarzt2025
[Therapy and healthcare applications in the treatment of adult attention deficit hyperactivity disorder: a review].
Review in Der Nervenarzt, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDigital interventions for day-to-day use in adult attention deficit hyperactivity disorder (ADHD) can be a useful further treatment option in addition to established ADHD treatments.
objectiveThis review of the literature presents the digital interventions for adults with ADHD in Germany that are currently available or in advanced development. MATERIAL AND
methodsThe aim is the identification and characterization of the digital interventions available for adult ADHD with a special focus on key features, modes of use, evidence achieved so far and maturity levels.
resultsIn total, six applications for adults with ADHD (attexis, AwareMe App, AwareMe Chatbot, hiFoon, NeuroNation MED, ORIKO) were identified. Clinical studies with initial proof of efficacy have already been carried out for some of the interventions, for the remainder clinical studies are planned or are currently being carried out.
conclusionOne of the digital interventions is already available on prescription in Germany as so-called digital healthcare apps (digitale Gesundheitsanwendungen, DiGA). Other developers plan to seek regulatory approval in the near future. Innovation potential is seen particularly in the translation of existing applications into new languages and in the future integration of mobile sensing functions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.